Pfizer has been given a "Neutral" rating by UBS, with a target price of $31 per share.
The termination of the lung cancer study involving the antibody Sasanlimab has raised concerns due to high dropout rates.
Analyst Trung Huynh is worried that these issues could also have a negative impact on the ongoing phase III bladder cancer study.
The implications of these developments for Pfizer's future prospects, particularly in the oncology sector, are highlighted in the commentary.
The outcomes of these studies will be closely monitored by the market as they could significantly influence investor sentiment and the company's stock performance.